Insulet (NASDAQ:PODD) Reaches New 12-Month Low – Time to Sell?

Insulet Corporation (NASDAQ:PODD) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $205.11 and last traded at $208.01, with a volume of 792667 shares changing hands. The stock had previously closed at $208.22.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. Zacks Research lowered Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Citigroup cut their target price on Insulet from $345.00 to $338.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Truist Financial reduced their target price on Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Finally, TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a research note on Monday, January 26th. Twenty equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $354.24.

Insulet Stock Down 0.1%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock has a market cap of $14.64 billion, a price-to-earnings ratio of 59.43, a price-to-earnings-growth ratio of 1.25 and a beta of 1.42. The business’s 50 day moving average is $244.14 and its 200 day moving average is $287.40.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company’s revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 EPS. Equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.39% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of large investors have recently made changes to their positions in PODD. Rockefeller Capital Management L.P. boosted its holdings in shares of Insulet by 488.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 3,343 shares of the medical instruments supplier’s stock worth $950,000 after purchasing an additional 2,775 shares during the period. Corient Private Wealth LLC increased its stake in Insulet by 35.0% in the 4th quarter. Corient Private Wealth LLC now owns 14,595 shares of the medical instruments supplier’s stock valued at $4,160,000 after buying an additional 3,782 shares during the period. Sit Investment Associates Inc. increased its stake in Insulet by 13.9% in the 4th quarter. Sit Investment Associates Inc. now owns 18,634 shares of the medical instruments supplier’s stock valued at $5,297,000 after buying an additional 2,277 shares during the period. MidFirst Bank purchased a new stake in Insulet in the 4th quarter worth approximately $394,000. Finally, Kera Capital Partners Inc. lifted its position in Insulet by 92.0% in the 4th quarter. Kera Capital Partners Inc. now owns 1,966 shares of the medical instruments supplier’s stock worth $559,000 after buying an additional 942 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.